This message is from a sponsor. It should not be considered a recommendation or endorsement by Benzinga.

Enlivex Posts Fiscal Year 2025 $1.23B Profit & Diluted Earnings Per Share of $25.48

Enlivex Ltd. (NASDAQ: ENLV), a quality longevity company powered by a prediction markets treasury, reported net income of $1.23 billion and diluted EPS of $25.48 for fiscal year 2025, with total treasury and treasury-related derivative assets of $2.31 billion. Much of the profit was driven by appreciation in the Company’s treasury and treasury-related derivative assets.

The Company is advancing Allocetra™, a clinical-stage immunotherapy targeting inflammatory conditions associated with aging, while maintaining a treasury strategy linked to prediction markets infrastructure through the Rain protocol.

Read the full earnings report here.

This is a paid ad. Please see 17b disclosure here for more information.